Status:
UNKNOWN
Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Duchenne Muscular Distrophy (DMD)
Eligibility:
All Genders
2-15 years
Phase:
NA
Brief Summary
Duchenne muscular dystrophy (DMD) is the most common and devastating form of muscular dystrophy, caused by an X-chromosome gene mutation resulting in the absence of the protein dystrophin. Gene therap...
Eligibility Criteria
Inclusion
- Boy between 2 to 15 years old.
- Lack of any infectious disease in the last week before the study.
- Consent form signed by parents.
- Inclusion Criteria for DMD infant
- Clinical suspicion of Duchenne Muscular Dystrophy
- Inclusion Criteria for Control healthy Infant
- Lack of any antecedent of congenital cardiac, pulmonary or muscular disease including DMD.
Exclusion
- Subjects who are unable or unwilling to tolerate study constraints
- Parents of the subject unable or unwilling to undergo informed consent
- Subject with no rights from the national health insurance programme
Key Trial Info
Start Date :
November 7 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01823783
Start Date
November 7 2012
End Date
January 1 2021
Last Update
February 7 2020
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
UH Bordeaux
Bordeaux, France, 33076
2
UH Lille
Lille, France, 59037
3
Montpellier University Hospital
Montpellier, France, 34295
4
Necker Hospital
Paris, France, 75743